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Background
Tacrolimus (TAC) has been a mainstay of immunosuppressive therapy following pediatric renal
transplantation. TAC has a narrow therapeutic index, thus, frequent therapeutic drug monitoring is
employed to maximize efficacy and avoid toxicity. Dose adjustments based on measured TAC
trough levels are challenging, since the drug displays complex pharmacokinetic behavior that is
affected by a multitude of genetic, physiologic and environmental factors.
Objectives/Goal
With the goal of developing a clinician-driven TAC pharmacokinetic dosing tool, our initial
objectives were 1) to examine whether published TAC population pharmacokinetic (popPK)
models could serve as a foundation to the dosing tool, and 2) evaluate their performance predicting
TAC concentrations in an independent cohort of 58 kidney transplant recipients (age 1-20 years) at
Children’s Mercy (CM).
Methods/Design
We searched the Pubmed database for TAC popPK modelling reports in pediatric renal
transplantation. From the publications, we extracted estimated model parameters (i.e., thetas) and
covariates that were identified to significantly affect TAC levels. Population clearances, volumes of
distribution and absorption rate constants were then modelled for the CM cohort. For each
observed post-transplant drug level, population predicted trough concentration was estimated.
The predictive performance of each model was evaluated visually by plotting predicted vs.
measured TAC trough levels for the entire CM cohort, and numerically via bias (estimated as mean
residual error, MRE) and imprecision (estimated as root mean squared error, RMSE). Models were
finally assessed according to their strength of predictive performance, with the best model having
MRE closest to a value of 0 and lowest RMSE estimate. Summary statistics and analyses were
performed in Excel and R.

Results
Six pediatric popPK models were identified. All models reported TAC pharmacokinetics best
described by a 2-compartment structural model with first-order absorption preceded by a lag time,
and elimination from the central compartment. The following covariates were shown to
significantly affect TAC trough levels: CYP3A5 genotype, total body weight, hematocrit, donor
status (living vs. deceased), eGFR and gamma-glutamyl transferase levels. Four models consistently
underpredicted measured TAC levels, and two consistently overpredicted measured TAC levels
(MRE range: -27.3% to 65.2%). A high degree of variability between predicted and measured TAC
levels was noted for all models (RMSE range: 48.2% to 120%). The model with the best predictive
performance had the following estimates: MRE: -9.8%, RMSE: 54%.
Conclusions
Four popPK models predicted TAC trough levels sufficiently well on average, however none of the
evaluated models predicted individual TAC levels with high precision. This suggests that variability
in measured TAC levels cannot entirely be explained by the covariates nested in established
models. Development of a reliable and accurate dosing tool will require significant refinement of
existing models or the creation of a de novo model.

